All In Biotech

Drug Trial Radar · NCT06268613

A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy

A Phase I, Randomised, Double-blind, Three-arm, Parallel Group, Multicentre Study to Compare the Pharmacokinetics (PK), Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, European Union [EU] Sourced Keytruda, and the United States of America [US] Sourced Keytruda) in Subjects With Stage II-IIIA Non-small Cell Lung Cancer Following Complete Resection and Adjuvant Platinum-based Chemotherapy

Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 163 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

163

Actual

Start

Jan 16, 2024

Primary completion

Feb 19, 2026

Study completion Nov 2026

Sponsor

Lead sponsor
Samsung Bioepis Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare the amount of study drug in patients' blood to confirm that SB27 works in the same way as EU and US sourced Keytruda in early or locally advanced non-small cell lung cancer (NSCLC) patients who underwent surgery and adjuvant chemotherapy. The main question it aims to answer is: • What the body does to the study drug, which is called "pharmacokinetic" Participants will receive investigational product (IP) administration every 3 weeks, maximum 18 cycles over about 51 weeks and blood sample will be collected. Researchers will compare 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) to see if SB27 works in the same way as EU and US sourced Keytruda.

Conditions

  • Non-small Cell Lung Cancer Stage II
  • Non-small Cell Lung Cancer Stage IIIA

Interventions

  • SB27Drug

    Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks

  • EU sourced KeytrudaDrug

    Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks

  • US sourced KeytrudaDrug

    Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Concentration-time Curve (AUC) over the Dosing Interval at Cycle 1Time frame: At the end of Cycle 1 (each cycle is 21 days)
  2. Area Under the Concentration-time Curve (AUC) over the Dosing Interval at Cycle 6Time frame: At the end of Cycle 6 (each cycle is 21 days)

Locations

24 sites in 4 countries. Site status is shown where the registry gives one.

  • SB Investigative Site

    Gdansk, Poland

  • SB Investigative Site

    Otwock, Poland

  • SB Investigative Site

    Ansan, South Korea

  • SB Investigative Site

    Busan, South Korea

  • SB Investigative Site

    Daegu, South Korea

  • SB Investigative Site

    Hwasun, South Korea

  • SB Investigative Site

    Incheon, South Korea

  • SB Investigative Site

    Jinju, South Korea

  • SB Investigative Site

    Seongnam, South Korea

  • SB Investigative Site 3

    Seoul, South Korea

  • SB Investigative Site 4

    Seoul, South Korea

  • SB Investigative Site 5

    Seoul, South Korea

  • SB Investigative Site 6

    Seoul, South Korea

  • SB Investigative Site 1

    Suwon, South Korea

  • SB Investigative Site 2

    Suwon, South Korea

  • SB Investigative Site

    Ulsan, South Korea

  • SB Investigative Site

    Málaga, Spain

  • SB Investigative Site

    Jaén, Jaén, Spain

  • SB Investigative Site

    A Coruña, Santiago de Compostela, Spain

  • SB Investigative Site

    Adana, Turkey (Türkiye)

  • SB Investigative Site 1

    Ankara, Turkey (Türkiye)

  • SB Investigative Site 2

    Ankara, Turkey (Türkiye)

  • SB Investigative Site

    Istanbul, Turkey (Türkiye)

  • SB Investigative Site

    Izmir, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.